2025 Guidelines for the Evaluation and Management of Adults With Congenital Heart Disease
December 19, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
ritivixibat
Class :
Ileal bile acid transporter (IBAT) inhibitor
Brand Name :
N/A
Synonyms :
ritivixibat
Class :
Ileal bile acid transporter (IBAT) inhibitor
Dosage Forms & Strengths
It is under investigation for the treatment of liver diseases, cardiovascular disorders, gastrointestinal disorders, and liver diseases, like Alagille syndrome and PFIC
It is an investigational drug, and is developed for the treatment of several cholestatic liver diseases, including Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC)
Cardiovascular diseases, disorders of fatty acid metabolism and glucose utilization, gastrointestinal disorders, and liver diseases can all be treated with this drug
Not determined
Refer to adult dosing
Actions and Spectrum
Ritivixibat is a bile acid transport inhibitor that inhibits bile acid reabsorption in ileum and increasing bile acid excretion in feces.
Frequency not defined
None
Black Box Warning
None
Contraindication/Caution:
None
Pregnancy/Lactation
Pregnancy consideration:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
Ritivixibat inhibits bile acid transportation in ileum and increases the bile acid excretion, thereby decreasing bile acid reabsorption in the intestines.
Pharmacodynamics
ritivixibat reduces the liver damage from the liver cholestatic diseases like alagille syndrome and PFIC by decreasing bile acid reabsorption and promoting the feces elimination.
Pharmacokinetics
Limited information available on ADME.
Administration
The administration of ritivixibat is not known.
Patient information leaflet
Generic Name: ritivixibat
Why do we use ritivixibat?
Ritivixibat inhibits bile acid transport in ileum, reducing bile acid reabsorption in intestine, aiming to lower the bile acid toxic levels in liver and increase liver damage.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
